Is PSA a prostate marker rather than a cancer-specific test?

PSA is produced predominantly by prostate epithelial tissue. It is therefore best understood as a prostate-organ marker and a cancer-risk signal—not a test that identifies cancer uniquely. This distinction is particularly important when interpreting an isolated elevated result.

Clinical evidence

• PSA is associated with prostate cancer but cannot distinguish cancer from benign prostate conditions. In a meta-analysis of clinically referred symptomatic men, PSA ≥4 ng/mL had pooled sensitivity of 93% but specificity of only 20% for prostate cancer.
• Benign prostatic enlargement (BPH) can raise PSA. In a prospective cohort of 100 men with benign enlargement, PSA correlated strongly with prostate volume (Spearman rho 0.729; p<0.001). A larger gland may therefore account for part of an elevated PSA, but does not exclude coexisting cancer.
• Inflammation and infection can produce substantial, transient PSA elevations. Acute prostatitis and febrile urinary infection are recognized causes; PSA may take weeks to months to normalize after recovery, and occasionally longer after febrile UTI.
• Acute urinary retention can also materially increase PSA. One clinical study found mean PSA decreased from 9.8 ng/mL during retention to 5.05 ng/mL after two weeks of catheter drainage—approximately a 49% decline.

Mechanistic and practical interpretation

• Greater benign prostate volume provides more PSA-producing epithelial tissue. Inflammation, infection, retention, and recent prostate manipulation can increase serum PSA release or confound measurement.
• PSA testing is most interpretable when obtained outside active infection or retention and under consistent conditions. A repeat value after recovery—often several weeks later—can better approximate baseline, but a fall in PSA does not itself rule out cancer.
• Persistent elevation should be interpreted with prostate volume, examination findings, symptoms, and individualized urologic risk assessment; PSA density may add context but is not definitive.

Bottom line

• The claim is well supported: PSA is prostate-organ-specific rather than cancer-specific, and benign enlargement, inflammation/infection, urinary retention, and manipulation can elevate it. An elevated PSA warrants contextual follow-up, not an automatic cancer diagnosis or dismissal.